CN105997852B - 一种瑞加诺生注射液及其制备方法 - Google Patents
一种瑞加诺生注射液及其制备方法 Download PDFInfo
- Publication number
- CN105997852B CN105997852B CN201610321393.5A CN201610321393A CN105997852B CN 105997852 B CN105997852 B CN 105997852B CN 201610321393 A CN201610321393 A CN 201610321393A CN 105997852 B CN105997852 B CN 105997852B
- Authority
- CN
- China
- Prior art keywords
- parts
- injection
- rui jianuosheng
- rui
- jianuosheng
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- TUJSONSWGXRXST-CCQDYZPNSA-N CC(C)C1N=CN([C@]2(C)O[C@H](COC)CC2)C1=N Chemical compound CC(C)C1N=CN([C@]2(C)O[C@H](COC)CC2)C1=N TUJSONSWGXRXST-CCQDYZPNSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N2030/022—Column chromatography characterised by the kind of separation mechanism
- G01N2030/027—Liquid chromatography
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610321393.5A CN105997852B (zh) | 2016-05-15 | 2016-05-15 | 一种瑞加诺生注射液及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610321393.5A CN105997852B (zh) | 2016-05-15 | 2016-05-15 | 一种瑞加诺生注射液及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105997852A CN105997852A (zh) | 2016-10-12 |
CN105997852B true CN105997852B (zh) | 2018-10-09 |
Family
ID=57097817
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610321393.5A Active CN105997852B (zh) | 2016-05-15 | 2016-05-15 | 一种瑞加诺生注射液及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105997852B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106943347B (zh) * | 2017-04-17 | 2018-11-13 | 南京健友生化制药股份有限公司 | 瑞加德松注射液的放大生产方法 |
CN113908117B (zh) * | 2020-12-23 | 2022-11-08 | 常州方圆制药有限公司 | 瑞加德松注射液及其制备方法 |
CN113143857A (zh) * | 2021-05-08 | 2021-07-23 | 珠海润都制药股份有限公司 | 一种瑞加诺生注射液的制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1671399A (zh) * | 2002-07-29 | 2005-09-21 | Cv医药有限公司 | 利用a2a受体激动剂的心肌灌注显像 |
CN104224706A (zh) * | 2014-09-05 | 2014-12-24 | 国药集团国瑞药业有限公司 | 一种瑞加德松注射液及其制备方法 |
CN104513241A (zh) * | 2013-09-30 | 2015-04-15 | 浙江海正药业股份有限公司 | 瑞加德松新中间体及其制备方法和应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012149196A1 (en) * | 2011-04-27 | 2012-11-01 | Reliable Biopharmaceutical Corporation | Improved processes for the preparation of regadenoson and a new crystalline form thereof |
-
2016
- 2016-05-15 CN CN201610321393.5A patent/CN105997852B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1671399A (zh) * | 2002-07-29 | 2005-09-21 | Cv医药有限公司 | 利用a2a受体激动剂的心肌灌注显像 |
CN104513241A (zh) * | 2013-09-30 | 2015-04-15 | 浙江海正药业股份有限公司 | 瑞加德松新中间体及其制备方法和应用 |
CN104224706A (zh) * | 2014-09-05 | 2014-12-24 | 国药集团国瑞药业有限公司 | 一种瑞加德松注射液及其制备方法 |
Non-Patent Citations (4)
Title |
---|
一种合成2-巯基腺苷的新方法;夏然 等;《化学试剂》;20160131;第38卷(第1期);第70-72页 * |
瑞加德松有关物质的发现与合成;吴立前等;《中国医药工业杂志》;20151231;第46卷(第7期);第683-686页 * |
瑞加德松的全合成研究;刘伟 等;《上海医药》;20160229;第37卷(第3期);第73-75页 * |
瑞加德松的合成;罗海荣等;《中国医药工业杂志》;20141231;第45卷(第8期);第705-707页 * |
Also Published As
Publication number | Publication date |
---|---|
CN105997852A (zh) | 2016-10-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105997852B (zh) | 一种瑞加诺生注射液及其制备方法 | |
RU2403067C2 (ru) | СТАБИЛИЗИРОВАННЫЕ КОМПОЗИЦИИ ТЕХНЕЦИЯ-99m (99mTc) | |
FI78837B (fi) | Foerfarande foer framstaellning av en foer injektionsadministration laemplig, stabil och saltsyrahaltig vattenloesning av cis-platina. | |
CN112386571B (zh) | 一种稳定的丁苯酞氯化钠注射液、其制备方法及用途 | |
US8258166B2 (en) | Pharmaceutical composition | |
US20100249413A1 (en) | Stabilized pharmaceutical composition | |
CN105125480B (zh) | 一种硫辛酸的液体制剂及其制备方法 | |
CN112294756A (zh) | 一种苯磺顺阿曲库铵注射液及其制备方法 | |
CN111499553A (zh) | 一种帕立骨化醇及其注射剂的制备方法 | |
CN104523580A (zh) | 一种肌苷氯化钠注射液及其制备方法 | |
CN109528632A (zh) | 尼莫地平药物组合物、尼莫地平注射液及其制备方法 | |
CN103784438B (zh) | 一种复方氨基酸注射液15-hbc组合物及其制备方法 | |
CN106959347A (zh) | 环磷腺苷葡胺注射液药物组合物及其质控方法和制法 | |
WO2012120337A1 (en) | Aqueous paracetamol compositions and method of preparation | |
CN105106976B (zh) | 一种碘克沙醇注射液及其制备方法 | |
JP2021504460A (ja) | 没食子酸エピガロカテキン溶液 | |
Viswanathan et al. | Plasma protein binding interaction between valproic and salicylic acids in rhesus monkeys | |
CN111265474B (zh) | 一种帕立骨化醇注射液及其制备方法 | |
EP4029505A1 (en) | Injection containing p-boronophenylalanine | |
CN101129374A (zh) | 长春氟宁药物组合物及其制备方法与应用 | |
CN105796487A (zh) | 一种米力农注射液及其制备方法 | |
CN106511356B (zh) | 一种伊班膦酸钠组合物及其制备方法 | |
RU2229884C2 (ru) | Способ стабилизации раствора ципрофлоксацина для инфузий | |
Palak et al. | Formulation and Evaluation of Niosomal gel using Tretinoin and Clindamycin combination | |
CN102688186A (zh) | 一种含有长春西汀原料的药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information |
Address after: Park Road in Jiangning District of Nanjing city and Jiangsu province 211100 No. 18 Zijin Fangshan technology innovation special community building 903 room 5 Applicant after: Nanjing financial Polytron Technologies Inc Address before: Park Road in Jiangning District of Nanjing city and Jiangsu province 211100 No. 18 Zijin Fangshan technology innovation special community building 903 room 5 Applicant before: Nanjing Hairong Medical Science & Technology Co., Ltd. |
|
COR | Change of bibliographic data | ||
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20170126 Address after: Park Road in Jiangning District of Nanjing city and Jiangsu province 211100 No. 18 Zijin Fangshan technology innovation special community building 903 room 5 Applicant after: Nanjing financial Polytron Technologies Inc Applicant after: Nanjing Hai Mei Biological Medicine Co., Ltd. Address before: Park Road in Jiangning District of Nanjing city and Jiangsu province 211100 No. 18 Zijin Fangshan technology innovation special community building 903 room 5 Applicant before: Nanjing financial Polytron Technologies Inc |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP01 | Change in the name or title of a patent holder |
Address after: 211100 Room 903, 5 Building, Zijin Fangshan Science and Technology Venture Community, No. 18 Zhilan Road, Jiangning Science Park, Nanjing City, Jiangsu Province Patentee after: NANJING HERON PHARMACEUTICAL SCIENCE AND TECHNOLOGY Co.,Ltd. Patentee after: Nanjing rike sanitary products and Medicine Co.,Ltd. Address before: 211100 Room 903, 5 Building, Zijin Fangshan Science and Technology Venture Community, No. 18 Zhilan Road, Jiangning Science Park, Nanjing City, Jiangsu Province Patentee before: NANJING HERON PHARMACEUTICAL SCIENCE AND TECHNOLOGY Co.,Ltd. Patentee before: Nanjing Hai Mei Biological Medicine Co.,Ltd. |
|
CP01 | Change in the name or title of a patent holder |